Eli
Superluminal Medicines Secures $120M Series A Funding to Advance Membrane Receptor Drugs into Clinical Trials
Superluminal Medicines, Series A funding, membrane receptor drugs, clinical trials, AI-focused biotech, Eli Lilly investment
Superluminal Secures $120M Series A Funding to Advance Membrane Receptor Drugs into Clinical Trials
Superluminal, Eli Lilly, Series A funding, membrane receptor drugs, clinical trials, biotech, pharmaceuticals
OrsoBio Secures $67 Million in Funding for Next-Generation Obesity Treatments
OrsoBio, obesity drugs, Eli Lilly, Series B funding, weight loss medicines, metabolic disorders
Lilly’s Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Four Phase 3 Trials
Eli Lilly, efsitora alfa, once-weekly insulin, diabetes management, Phase 3 trials, non-inferiority, A1C reduction, insulin therapy.
Eli Lilly Partners with Genetic Leap in $409 Million AI-Driven Drug Development Deal
Eli Lilly, Genetic Leap, AI-powered drug deal, oligonucleotide therapy, pharmaceutical partnership
Eli Lilly’s Weekly Insulin Efsitora Alfa Shows Promising Results in Late-Stage Trials
Eli Lilly, weekly insulin, efsitora alfa, type 2 diabetes, Phase III trials, QWINT-1, QWINT-3, insulin therapy, diabetes management
BioAge Labs Files for IPO to Advance Obesity Treatment Candidate
BioAge Labs, IPO, obesity treatment, weight loss drugs, azelaprag, Eli Lilly, cardiometabolic biotech
BioAge Labs Files for $100 Million IPO to Advance Obesity Treatment Candidate Azelaprag
BioAge Labs, IPO, Obesity Treatment, Azelaprag, Eli Lilly, Novo Nordisk, Clinical Trials
Eli Lilly Launches Direct-to-Consumer Sales of Zepbound for Weight Loss
Eli Lilly, Zepbound, weight loss medication, direct-to-consumer sales, affordable pricing, obesity treatment
Lilly’s Tirzepatide Demonstrates Significant Reduction in Diabetes Risk and Sustained Weight Loss in Overweight Adults
tirzepatide, diabetes risk reduction, sustained weight loss, overweight adults, pre-diabetes, obesity, Eli Lilly, Mounjaro, Zepbound